-
Mashup Score: 14
This cohort study of men treated at US urology practices uses a national disease registry to analyze trends and variation in the use of active surveillance for the treatment of low-risk prostate cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Active surveillance (AS), Prostate Cancer (PC), intraductal carcinoma, IDC-P, cribriform, radical prostatectomy, low-risk prostate cancer (PC), factor of IDC-P or cribriform patterns in radical prostatectomy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for #ActiveSurveillance: data from the PRIAS-JAPAN study. #BeyondTheAbstract on UroToday > https://t.co/1iAjaLlRxl @TohiYoichiro https://t.co/u2ADQ1xcv2
-
-
Mashup Score: 5
ASCO GU 2023 stage 1 seminoma testis in active surveillance relapse, predicting relapse in clinical stage 1 seminoma, European Association of Urology Testicular Cancer Guidelines Panel.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
@Uroweb #TesticularCancer Guidelines Panel: A new prognostic factor risk group classification for pts with clinical stage 1 seminoma in #ActiveSurveillance. Presented by Robert Hamilton @UofT. @ASCO #GU23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/wMlFVOriim https://t.co/uRioFkxgcR
-
-
Mashup Score: 3SUO 2022: Use of Exogenous Testosterone in The Setting Of Screening, Active Surveillance, and After Treatment of Localized Disease - 1 year(s) ago
SUO 2022 testosterone replacement therapy among patients with prostate cancer, absence of evidence linking testosterone therapy to the development of prostate cancer, TRAVERSE trial, association between testosterone and prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Use of exogenous testosterone in the setting of screening, #ActiveSurveillance, and after treatment of localized disease. Presentation by @DrMohitKhera @bcmhouston. #SUO22 written coverage by @WallisCJD @UofT > https://t.co/lBcU0iAunW @UroOnc @SUO_YUO https://t.co/Rc8ZUIE3BR
-
-
Mashup Score: 0Safe to Expand Limits of Active Surveillance in Thyroid Cancer? - 2 year(s) ago
New research shows extending active surveillance limits for tumor sizes up to 2 cm showed no increases in adverse outcomes or mortality, but ‘the expanded parameters are quite controversial.’
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Expanding eligibility for #activesurveillance in low-risk papillary thyroid cancer appears to be safe, a new prospective trial indicates. #OncTwitter https://t.co/g8sGIadi7W
-
-
Mashup Score: 1Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz - 2 year(s) ago
Laurence Klotz joins Phillip Koo at the 13th International Uro-Oncology Congress in São Paulo, Brazil in a discussion on Active Surveillance (AS), High-intensity focused ultrasound (HIFU), and focal therapy in Latin America and developing countries. There are challenges with active surveillance in developing countries that might not have formal prostate cancer screening programs, a lack of…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Barriers and opportunities in #ActiveSurveillance, #HIFU, and #FocalTherapy in #LatinAmerican countries. @KlotzLaurence @Sunnybrook joins @PhillipKooMD @BannerHealth to discuss at the 13th International Uro-Oncology Congress. #WatchNow > https://t.co/6m0wnyMRS4 https://t.co/4gEmjdcOAj
-
-
Mashup Score: 0Risk of progression following a negative biopsy in prostate cancer active surveillance - 2 year(s) ago
Currently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following negative biopsy findings, we assessed the risk of converting to active treatment, any subsequent upgrading, volume progression (>33% positive cores), and serious…
Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What is the role of first biopsy in patients on AS? Find out more on : https://t.co/zpbTxojXVa #pcsm #CancerResearch #activesurveillance @wandering_gu @bjartell @TDorffOnc @onco_uroloog https://t.co/qUW7SiAioZ
-
-
Mashup Score: 0
ESMO 2022 Analysis of ENACT, Enzalutamide in Men Undergoing Active Surveillance, ENACT trial assessed whether one year of enzalutamide could reduce disease progression, Decipher GRID platform.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Transcriptome-based prognostic and predictive biomarker analysis of #ENACT: a randomized controlled trial of enzalutamide in men undergoing #ActiveSurveillance. Presented by @ashleyrossmdphd @NUFeinbergMed. #ESMO22 written coverage by @WallisCJD > https://t.co/RisBsNiYwL @myESMO https://t.co/6f7D2REn8M
-
-
Mashup Score: 1
Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn’t. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Risk stratification for localized #ProstateCancer. @dr_coops @UCSFCancer joins @charlesryanmd @PCFnews discussing which patients should recieve #ActiveSurveillance and who should not. #WatchNow on UroToday > https://t.co/BENj64GYfm @ASCO #GU22 @AmerUrological #AUA22 https://t.co/5Td7CPMCP6
-
-
Mashup Score: 2Episode 184: Active surveillance in prostate cancer and the seeds of doubt by The Uromigos - 2 year(s) ago
Declan Murphy and Matt Cooperberg debate this controversial issue.
Source: AnchorCategories: Hem/Oncs, Latest HeadlinesTweet-
A nice debate on #activesurveillance in #prostatecancer and the role of clinical investigation of systemic therapy in this population. https://t.co/EGZcu1l2ZJ Listen, then vote: Should systemic/local therapy be investigated in clinical trials for AS patients in prostate cancer?
-
Trends and Variation in Use of #Activesurveillance for Low-risk #Prostatecancer, now out in @JAMANetworkOpen https://t.co/AeRmO7rx4v. Data from over 20K men in the @AmerUrological #AQUARegistry: Nat'l rates of AS up from 26% to 60% since 2014, but variation remains extreme: https://t.co/OanpAkGmT5